Result of WRAP Retail Offer

Further to its announcements made on 1 October 2025 (the "Launch Announcements"), MedPal AI plc is pleased to announce the successful completion of the Placing and WRAP Retail Offer (together, the "Fundraise"), at the Issue Price of 8 pence per share.

The Fundraise has raised, in aggregate, gross proceeds of approximately £545,304 comprising £400,000 pursuant to the Placing and £145,304 pursuant to the WRAP Retail Offer. Accordingly, the Company will issue 6,816,305 new ordinary shares ("New Ordinary Shares") to investors in the Fundraise.

The proceeds of the Fundraise will be used to progress the Company's strategy with regard to the recently announced acquisition of assets from Universal Pharmacy Ltd (in administration), which will enable MedPal AI to establish itself in the rapidly growing GLP-1 agonist market for obesity treatment, including drugs such as semaglutide (eg. Ozempic and Mounjaro).

Settlement of the New Ordinary Shares and Admission are expected to take place on or around 8.00 a.m. on 8 October 2025. The Fundraise is conditional upon, among other things, Admission (as defined below) becoming effective.

Admission and Total Voting Rights

Application has been made for the 6,816,305 New Ordinary Shares to be admitted to trading on AIM on or around 8 October 2025 ("Admission"). The New Ordinary Shares will rank pari passu with the Ordinary Shares of the Company in issue.

Following Admission, the Company's issued share capital will comprise 419,899,640 Ordinary Shares of 0.02p each, with each share carrying the right to one vote, therefore the total number of voting rights in the Company will be 419,899,640. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in the Launch Announcements, unless the context provides otherwise.

The Directors of the Company are responsible for the contents of this announcement.